Chief Executive Officer, Chief Financial Officer, Treasurer and Secretary, Director
Mr. Shallcross was appointed as the Company’s Interim Chief Executive Officer on December 5, 2017 and has served as the Company’s Chief Financial Officer, Treasurer and Secretary since joining the Company in June 2015. Mr. Shallcross brings to the Company operational, financial and international biotech industry experience, as well as an established track record at leading the financial development and strategy for several publicly traded biotech companies. From May 2013 through May 2015, Mr. Shallcross served as Executive Vice President and Chief Financial Officer of Nuo Therapeutics, Inc. (formerly Cytomedix, Inc.). In January 2016, Nuo Therapeutics, Inc. filed a voluntary petition for relief under Chapter 11 of the U.S. Bankruptcy Code in the United States Bankruptcy Court for the District of Delaware and on April 25, 2016, the Bankruptcy Court entered an order granting approval of Nuo’s plan of reorganization. From July 2012 to May 2013, Mr. Shallcross held the offices of Executive Vice President, Chief Financial Officer and Treasurer of Empire Petroleum Partners, LLC, a motor fuel distribution company. From July 2011 to March 2012, Mr. Shallcross was Acting Chief Financial Officer of Senseonics, a privately-held medical device company located in Germantown, MD. From January 2009 to March 2011, he served as Executive Vice President and Chief Financial Officer of Innocoll AG (formerly privately held Innocoll Holdings, Inc.), a global, commercial-stage biopharmaceutical company specializing in the development and commercialization of collagen-based products. He also served for four years as the Chief Financial Officer and Treasurer of Vanda Pharmaceuticals, Inc., leading the company through its successful IPO and follow-on offering and previously served as the Senior Vice President and Chief Financial Officer of Middlebrook Pharmaceuticals, Inc. (formerly Advancis Pharmaceutical Corporation). In addition, Mr. Shallcross also served as the Chief Financial Officer of Bering Truck Corporation. He holds an MBA from the University of Chicago’s Booth School of Business, a Bachelor of Science degree in Accounting from the University of Illinois, Chicago, and is a Certified Public Accountant in the State of Illinois.
Michael Kaleko, MD, PhD
Senior Vice President, Research & Development
Dr. Kaleko, Senior Vice President, Research & Development, joined Synthetic Biologics in March 2012 as the Scientific Director. He brings over 20 years of experience in the biotechnology/pharmaceutical sector, including eleven years at Genetic Therapy, Inc., a Novartis company, where he developed multiple gene transfer and gene expression platform technologies for hemophilia, cancer, diabetes and ocular diseases. In 2002, he co-founded Advanced Vision Therapies, Inc. to develop treatments for eye diseases, including an anti-inflammatory biological for multiple ocular indications. After selling the company in 2005, he continued as Chief Scientific Officer until 2010. Dr. Kaleko has published 62 peer-reviewed articles, filed over 30 patent applications and received the Novartis Pharma Research and Development Business Excellence Award for his work in the diabetes field. Dr. Kaleko earned ScB, MD and PhD degrees from Brown University, served his medical residency in internal medicine at Vanderbilt University and completed a fellowship in clinical endocrinology with a focus in gene therapy research at the University of Washington, Seattle.
Vince Wacher, PhD
Head of Corporate & Product Development
Vince Wacher is a biotechnology/pharmaceutical industry professional with 25 years of experience successfully leading corporate strategy, partnering, research, product development, and intellectual property programs for start-ups, small companies and new business units within large companies. Prior to his role with Synthetic Biologics Inc., Vince was CEO of Verva Pharmaceuticals Ltd., where he advanced a repurposed medicine to successful Phase 2 clinical proof-of-concept testing in type 2 diabetes and discovered a new mitochondrial mode-of-action with expansion applications in NAFLD/NASH, weight loss and mitochondrial diseases. Vince has designed, implemented, and/or analyzed discovery, preclinical and clinical programs in diverse therapeutic areas, including metabolic, cardiovascular, gastrointestinal, oncology, infection, immunosuppression, drug delivery and drug repurposing. He received an Eastman Business Builder Award in 2004 for his work with Eastman Chemical Company in advancing their drug delivery technologies. Vince graduated with the University Medal in chemistry from the University of NSW and received his PhD from the University of California, Berkeley, where he worked in pesticide chemistry and toxicology. He transitioned into the pharmaceutical industry as a post-doctoral scholar in pharmacokinetics and metabolism with Dr. Leslie Z. Benet at the University of California, San Francisco.